TNON Stock Catalyst: Tenon Medical Receives FDA Clearance for Expanded Use of Catamaran SI Joint Fusion System

Tenon Medical, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance for an expanded indication of its Catamaran SI Joint Fusion System. The system is now approved to augment spinal fusion procedures, providing additional support and stability.

This clearance broadens the application of Tenon Medical's Catamaran System, potentially increasing its utility in various surgical scenarios. The company did not provide specific financial projections or timelines for the expanded use.

Tenon Medical has a free float of 8,209,700 shares and 8,603,000 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.